Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7

Molecular Therapy

Volumn 22, Issue 9, 2014, Pages 1635-1642

  Ramachandran, Pavitra S ^a   Boudreau, Ryan L ^b   Schaefer, Kellie A ^b   La Spada, Albert R ^c   Davidson, Beverly L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 7; ATXN7 PROTEIN, MOUSE; NERVE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIN 7 GENE; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PURKINJE CELL; RNA INTERFERENCE; RNA SEQUENCE; SPINOCEREBELLAR DEGENERATION; ALLELE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; MOTOR ACTIVITY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; SPINOCEREBELLAR ATAXIAS;

ALLELES; ANIMALS; ATAXIN-7; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MUTATION; NERVE TISSUE PROTEINS; PURKINJE CELLS; RNA INTERFERENCE; SPINOCEREBELLAR ATAXIAS;

EID: 84964314523     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.108     Document Type: Article

References (49)

1. Michalik, A, Martin, JJ and Van Broeckhoven, C (2004). Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy. Eur J Hum Genet 12: 2-15.
2. Whitney, A, Lim, M, Kanabar, D and Lin, JP (2007). Massive SCA7 expansion detected in a 7-month-old male with hypotonia, cardiomegaly, and renal compromise. Dev Med Child Neurol 49: 140-143.
3. Michalík, A, Del-Favero, J, Mauger, C, Löfgren, A and Van Broeckhoven, C (1999). Genomic organisation of the spinocerebellar ataxia type 7 (SCA7) gene responsible for autosomal dominant cerebellar ataxia with retinal degeneration. Hum Genet 105: 410-417.
4. Johansson, J, Forsgren, L, Sandgren, O, Brice, A, Holmgren, G and Holmberg, M (1998). Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. Hum Mol Genet 7: 171-176.
5. Garden, GA and La Spada, AR (2008). Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum 7: 138-149.
6. Holmberg, M, Duyckaerts, C, Dürr, A, Cancel, G, Gourfinkel-An, I, Damier, P et al. (1998). Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 7: 913-918.
7. Palhan, VB, Chen, S, Peng, GH, Tjernberg, A, Gamper, AM, Fan, Y et al. (2005). Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci USA 102: 8472-8477.
8. Helmlinger, D, Hardy, S, Abou-Sleymane, G, Eberlin, A, Bowman, AB, Gansmüller, A et al. (2006). Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol 4: e67.
9. Furrer, SA, Waldherr, SM, Mohanachandran, MS, Baughn, TD, Nguyen, KT, Sopher, BL et al. (2013). Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Hum Mol Genet 22: 890-903.
10. Scholefield, J, Greenberg, LJ, Weinberg, MS, Arbuthnot, PB, Abdelgany, A and Wood, MJ (2009). Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One 4: e7232.
11. Furrer, SA, Mohanachandran, MS, Waldherr, SM, Chang, C, Damian, VA, Sopher, BL et al. (2011). Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. J Neurosci 31: 16269-16278.
12. Guyenet, SJ, Furrer, SA, Damian, VM, Baughan, TD, La Spada, AR, Garden, GA. (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp 39: e1787.
13. Boudreau, RL, Spengler, RM, Hylock, RH, Kusenda, BJ, Davis, HA, Eichmann, DA et al. (2013). siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res 41: e9.
14. Boudreau, RL and Davidson, BL (2012). Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol 507: 275-296.
15. Keiser, MS, Geoghegan, JC, Boudreau, RL, Lennox, KA and Davidson, BL (2013). RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis 56: 6-13.
16. Xia, H, Mao, Q, Eliason, SL, Harper, SQ, Martins, IH, Orr, HT et al. (2004). RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820.
17. Rodríguez-Lebrón, E, Costa, Md, Luna-Cancalon, K, Peron, TM, Fischer, S, Boudreau, RL et al. (2013). Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther 21: 1909-1918.
18. Chou, AH, Yeh, TH, Ouyang, P, Chen, YL, Chen, SY and Wang, HL (2008). Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 31: 89-101.
19. Auerbach, W, Hurlbert, MS, Hilditch-Maguire, P, Wadghiri, YZ, Wheeler, VC, Cohen, SI et al. (2001). The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 10: 2515-2523.
20. Garden, GA, Libby, RT, Fu, YH, Kinoshita, Y, Huang, J, Possin, DE et al. (2002). Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci 22: 4897-4905.
21. Custer, SK, Garden, GA, Gill, N, Rueb, U, Libby, RT, Schultz, C et al. (2006). Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 9: 1302-1311.
22. Gatchel, JR, Watase, K, Thaller, C, Carson, JP, Jafar-Nejad, P, Shaw, C et al. (2008). The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci U S A 105: 1291-1296.
23. McCullough, SD, Xu, X, Dent, SY, Bekiranov, S, Roeder, RG and Grant, PA (2012). Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes. Proc Natl Acad Sci USA 109: 21319-21324.
24. Friedrich, B, Euler, P, Ziegler, R, Kuhn, A, Landwehrmeyer, BG, Luthi-Carter, R et al. (2012). Comparative analyses of Purkinje cell gene expression profiles reveal shared molecular abnormalities in models of different polyglutamine diseases. Brain Res 1481: 37-48.
25. Hansen, ST, Meera, P, Otis, TS and Pulst, SM (2013). Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum Mol Genet 22: 271-283.
26. Clark, HB, Burright, EN, Yunis, WS, Larson, S, Wilcox, C, Hartman, B et al. (1997). Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 17: 7385-7395.
27. Ström, AL, Forsgren, L and Holmberg, M (2005). A role for both wild-type and expanded ataxin-7 in transcriptional regulation. Neurobiol Dis 20: 646-655.
28. Helmlinger, D, Hardy, S, Sasorith, S, Klein, F, Robert, F, Weber, C et al. (2004). Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13: 1257-1265.
29. Kiehl, TR, Nechiporuk, A, Figueroa, KP, Keating, MT, Huynh, DP and Pulst, SM (2006). Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun 339: 17-24.
30. Matilla, A, Roberson, ED, Banfi, S, Morales, J, Armstrong, DL, Burright, EN et al. (1998). Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J Neurosci 18: 5508-5516.
31. Switonski, PM, Fiszer, A, Kazmierska, K, Kurpisz, M, Krzyzosiak, WJ and Figiel, M (2011). Mouse ataxin-3 functional knock-out model. Neuromolecular Med 13: 54-65.
32. La Spada, AR, Fu, YH, Sopher, BL, Libby, RT, Wang, X, Li, LY et al. (2001). Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31: 913-927.
33. Yoo, SY, Pennesi, ME, Weeber, EJ, Xu, B, Atkinson, R, Chen, S et al. (2003). SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37: 383-401.
34. Helmlinger, D, Abou-Sleymane, G, Yvert, G, Rousseau, S, Weber, C, Trottier, Y et al. (2004). Disease progression despite early loss of polyglutamine protein expression in SCA7 mouse model. J Neurosci 24: 1881-1887.
35. Latouche, M, Fragner, P, Martin, E, El-Hachimi, KH, Zander, C, Sittler, A et al. (2006). Polyglutamine and polyalanine expansions in ataxin7 result in different types of aggregation and levels of toxicity. Mol Cell Neurosci 31: 438-445.
36. Vos, MJ, Zijlstra, MP, Kanon, B, van Waarde-Verhagen, MA, Brunt, ER, Oosterveld- Hut, HM et al. (2010). HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones. Hum Mol Genet 19: 4677-4693.
37. Simões, AT, Gonçalves, N, Koeppen, A, Déglon, N, Kügler, S, Duarte, CB et al. (2012). Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 135(Pt 8): 2428-2439.
38. Tsunemi, T, Ashe, TD, Morrison, BE, Soriano, KR, Au, J, Roque, RA et al. (2012). PGC- 1rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 4: 142ra97.
39. Chort, A, Alves, S, Marinello, M, Dufresnois, B, Dornbierer, JG, Tesson, C et al. (2013). Interferon induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain 136: 1732-1745.
40. Keiser, MS, Boudreau, RL and Davidson, BL (2014). Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol Ther 22: 588-595.
41. do Carmo Costa, M, Luna-Cancalon, K, Fischer, S, Ashraf, NS, Ouyang, M, Dharia, RM et al. (2013). Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther 21: 1898-1908.
42. Rüb, U, Brunt, ER and Deller, T (2008). New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 21: 111-116.
43. Schöls, L, Bauer, P, Schmidt, T, Schulte, T and Riess, O (2004). Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3: 291-304.
44. Nóbrega, C, Nascimento-Ferreira, I, Onofre, I, Albuquerque, D, Hirai, H, Déglon, N et al. (2013). Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS One 8: e52396.
45. Alves, S, Nascimento-Ferreira, I, Dufour, N, Hassig, R, Auregan, G, Nóbrega, C et al. (2010). Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum Mol Genet 19: 2380-2394.
46. Noma, S, Ohya-Shimada, W, Kanai, M, Ueda, K, Nakamura, T and Funakoshi, H (2012). Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7. Neurosci Res 73: 115-121.
47. Urabe, M, Ding, C and Kotin, RM (2002). Insect cells as a factory to produce adenoassociated virus type 2 vectors. Hum Gene Ther 13: 1935-1943.
48. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
49. Chen, C, Ridzon, DA, Broomer, AJ, Zhou, Z, Lee, DH, Nguyen, JT et al. (2005). Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.